How does adefovir dipivoxil actually stop hepatitis B virus from multiplying inside my liver?
Adefovir dipivoxil blocks reverse transcriptase, the enzyme hepatitis B virus uses to copy its genetic code. This slows viral replication by 1,000–10,000 fold within 12 weeks, giving your immune system time to clear infected cells and prevent cirrhosis [1].
Here's the federal trial data: adefovir monotherapy reduces hepatitis B viral load (HBV DNA) by 3–4 log in 60–80% of treatment-naïve patients within 12 weeks [1][3]. HBeAg seroconversion (loss of the e-antigen marker) occurs in 12–20% by week 96, lower than lamivudine alone but improved with combination therapy [1][7]. These numbers come from randomized controlled trials and real-world cohort studies spanning 2007–2019.
Inside your liver cells, adefovir dipivoxil is converted to its active form (adefovir diphosphate) and acts as a fake building block. When the hepatitis B virus tries to copy its RNA using reverse transcriptase, it accidentally incorporates adefovir instead of the real nucleotide. This breaks the chain reaction and stops viral replication dead [9]. Think of it like a puzzle piece that looks right but doesn't fit—the virus's copying machine jams.
Real-world trade-off: adefovir works steadily but slowly. You won't feel better overnight. Viral suppression takes 12 weeks; HBeAg seroconversion takes 1–2 years or longer. If you're HBeAg-positive and don't seroconvert by week 48, your doctor may add peginterferon or switch to a combination regimen [1][7]. Cost: $781/month retail, but generic and patient assistance programs drop this to $50–200.
Ask your doctor: 'What's my HBeAg status and baseline HBV DNA level?' These two numbers predict whether you'll seroconvert and how long treatment will take. If you're HBeAg-negative, adefovir alone may be enough; if HBeAg-positive, combination therapy might be faster [1].